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Lung Transplant for Interstitial 
Lung Diseases
Brandon Nokes, Eugene Golts and Kamyar Afshar
Abstract
Lung transplant is an important treatment modality for select cases of advanced 
interstitial lung disease. However, the pre- and postoperative management requires sev-
eral unique considerations. The decision to transplant is based largely on clinical sever-
ity of illness and the lung allocation score. Transplant improves overall mortality across 
the interstitial lung diseases, though not all ILD subtypes experience equal benefit from 
lung transplant. Broadly speaking, there is no difference in benefit between single- and 
bilateral-lung transplants, though we will discuss some important clinical nuances to 
this decision as well. Lastly, there are a number of immunosuppression, coagulation, 
and malignancy risk considerations that must be carefully understood in caring for the 
lung transplant patient. This chapter will provide a general overview of the indications 
for lung transplant, risk stratification for lung transplant across the interstitial lung 
diseases, as well as general postoperative management details.
Keywords: interstitial lung diseases, usual interstitial pneumonia, lung transplant, 
lung allocation score, immunosuppression
1. Introduction
Lung transplantation is a therapeutic surgical option for selected patients with 
severe pulmonary disease who are refractory to medical therapy and continue to 
have progressive clinical deterioration [1]. As is discussed elsewhere in this book, 
the idiopathic interstitial pneumonias (IIPs) that require lung transplantation 
include idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP), 
nonspecific interstitial pneumonia (NSIP), and acute interstitial pneumonia (AIP). 
The non-IIP ILD groups that are routinely evaluated for lung transplant include 
sarcoidosis, hypersensitivity pneumonitis (HP), rheumatologically associated UIP 
and NSIP, as well as lymphangioleiomyomatosis (LAM).
The general guidelines for lung transplantation consideration include (1) high 
(>50%) risk of death from lung disease within 2 years without transplant, (2) high 
(>80%) likelihood of surviving at least 90 days after lung transplantation, and (3) 
high (>80%) likelihood of 5-year posttransplant survival from a general medical 
perspective provided that there is adequate graft function [1]. Within the United 
States, between 1995 and 2015, ILDs accounted for 29.7% (n = 14,828) of lung 
transplants [1]. Collectively, the ILDs were the second most common indication for 
transplant behind chronic obstructive pulmonary disease without alpha-1-antitryp-
sin deficiency [1]. Of those patients, 6956 received single-lung transplant, and 7872 
received bilateral-lung transplants [1]. Importantly, the ILD diagnostic subclasses 
were subdivided into idiopathic interstitial pneumonias (IIP) (n = 12,243) as well 
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as ILD, not-IIP (n = 2585) (Table 1). Sarcoidosis, obliterative bronchiolitis (OB), 
and connective tissue disorder (CTD) were also listed diagnostic indications, and 
so there exists the potential for overlapping and misclassification of the underlying 
disease leading to lung transplant in a small proportion of cases. Irrespective of the 
subtype, ILDs present a unique challenge from pretransplant selection to postopera-
tive care. The pre- and posttransplant clinical courses for each of these pathologies 
will be detailed within this chapter.
2. The lung allocation score (LAS) and the decision to transplant
An important part of the preoperative evaluation is individual assessment of 
patient risk with and without transplant. Some European countries, like France and 
Switzerland, have a national urgency list. Others, including the United Kingdom, 
allocate donor lungs according to individual transplant center decisions. More than 
60% of the worldwide lung transplant activity, however, is allocated by the lung 
allocation score (LAS) [2]. The LAS has been adopted in many countries as a means 
of minimizing waitlist mortality [2]. The LAS is a calculated score (from 0 to 100) 
used to predict waitlist survival probability with and without a lung transplant for 
patients over the age of 12. Higher LAS scores impart a higher likelihood of waitlist 
mortality and allow for a prognostic stratification within regional transplant wait-
lists and associated organ allocation preference [2]. This multifactorial system com-
bines pulmonary function data with clinical comorbidity data. The implementation 
of this system has resulted in a substantial reduction in waitlist mortality and for the 
more expeditious mobilization of organs on a needs-based assessment [3]. Moreover, 
the median waitlist time in the United States has dropped from 4.1 to 2.1 months 
since the adoption of the LAS [2]. As such, the LAS has since been adopted in a num-
ber of other countries’ transplant programs [4, 5]. Similar OLT outcomes research 
has been conducted on healthcare-related quality of life (HRQL) after transplant, 
and in general, higher LAS imparts a greater improvement in HRQL after OLT [6]. 
This benefit appears to diminish with greater age, especially after age 65 [6].
Despite the shorter waitlist time with higher LAS score, some patients may 
remain on the waitlist for longer periods of time. This is a reflection of a number of 
logistic limitations underpinning the lung transplant process. Notably, the number 
of available lung allografts does not meet the current US or global need. Up to 
Table 1. 
Common drug-drug interactions with immunosuppressants—adapted from [37].
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20% of lung transplant candidates are inactivated or die before an adequate donor 
becomes available [7]. Moreover, explanted lungs are inherently fragile, which fur-
ther complicates the transplant process. Recipient underlying lung disease greatly 
matters in the type of transplant procedure required, e.g., unilateral vs. bilateral 
OLT. Donor and recipient lung size match is essential for adequate function of the 
allograft as well as survival [8]. Shorter patients may require lung donors from 
pediatric patients. However, pediatric lungs are first offered to pediatric candidates 
(age < 18 years) before they become available to other potential recipients.
Donors and recipient ABO blood type and human leukocyte antigen (HLA) 
compatibility must also be considered. Ideally, patients will have absent panel-
reactive antibodies (PRA). Notably, only 69.8% of lung transplant candidates had 
0% PRA since 2009. Patients with a higher PRA, particularly PRA greater than 
25%, have a higher 30-day and overall mortality [9]. This makes the waitlist time 
for an appropriate crossmatch significantly longer and can potentially exclude the 
candidate from transplantation due to elevated risk of rejection.
The underlying diagnosis necessitating transplant also impacts the LAS. With 
respect to ILD, individuals with IPF and sarcoidosis are more likely to have a higher 
LAS than more common diagnoses such as COPD [3]. With LAS scores greater than 
60, individuals with IPF have a greater risk of posttransplant mortality. Although 
no strict stratification exists to say at which LAS transplant should be avoided, this 
decision is left to local transplant centers when the risk is exceedingly high [3].
3. Idiopathic pulmonary fibrosis (IPF) lung transplant overview
Given the relative preponderance of IPF as a pretransplant diagnosis in com-
parison to the other ILDs, a brief overview of IPF outcomes following transplant 
is included here. The most common of the ILDs to necessitate transplant is IPF, 
which accounts for roughly 46% of patients on the lung transplant waiting list 
according to 2011 data from the Organ Procurement and Transplantation Network 
(OPTN) [10]. Importantly, IPF has no definitive treatment and an average survival 
of 2–3 years after diagnosis. It is associated with older age, male sex, and smoking 
history. It has also been associated with shortened telomere length, both in familial 
and sporadic forms [11]. This finding has been demonstrated in both peripheral 
blood leukocytes and postmortem lung tissue samples [11]. There are no targeted 
therapies readily available to curtail this epigenetic proclivity, but as IPF progresses, 
OLT remains a life-saving measure, with a median survival of 4.5 years after 
transplant for both bilateral- (BLT) and single-lung transplant (SLT) [12]. A recent 
meta-analysis suggested that those with BLT may have improved survival when 
compared to SLT, but this may be a result of selection bias [12]. Importantly, only 
those with end-stage bronchiectasis and idiopathic pulmonary arterial hypertension 
(IPAH) require BLT, and essentially all other diagnoses are suitable for SLT [12].
The clinical time course for IPF is heterogeneous, but there is invariably a clinical 
and functional decline, and many of these patients will have to go for transplant 
(Figure 1) [13]. The survival after transplant is the poorest for IPF relative to other 
indications for OLT, with the exception of re-transplant (Figure 2) [1]. As noted, the 
implementation of the LAS has allowed more rapid allocation of allografts for IPF 
and has improved prognosis tremendously. Further, although the median FVC for 
IPF at time of transplant is ~40–45%, this improves to 65% after transplant, contin-
gent on selecting appropriate donor size [14]. Predicted total lung capacity (pTLC) 
can be used to approximate appropriate donor lung size for SLT or BLT [14]. In the 
absence of postoperative graft dysfunction, improvements can also be expected in 
HRQL, 6-minute walk test (6MWT), PaO2, and dyspnea severity [15, 16].
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4. Issues addressed while awaiting lung transplantation
4.1 Short telomere length
Rare mutations in the telomere pathways (NAD1, PARN, RTELI, TERC, TERT) 
are found in familial pulmonary fibrosis [11, 17]. Having short telomere length is 
characterized by earlier onset of IPF, associated liver disease, impaired CMV immu-
nity, and bone marrow suppression [11, 17, 18]. Newton et al. conducted an observa-
tion cohort study of IPF patients who underwent lung transplantation [19]. Patients 
were stratified into two groups based on the telomere length; 32 patients were in 
Group 1 (telomere length < 10th percentile). They were compared to the 56 patients 
in Group 2 (telomere length ≥ 10th percentile). There were no difference between 
the two groups with regard to baseline demographics and severity of lung disease. 
Figure 1. 
Clinical course of patients with idiopathic pulmonary fibrosis. Many follow the course of the slow progressive 
decline. A minority will have a rapidly progressive course. An acute exacerbation can occur at any point in the 
course of functional decline. Rapidly progressive; acute exacerbations; and slowly progressive. Adapted from [51].
Figure 2. 
Kaplan-Meier survival by diagnosis for adult lung transplants performed between January 1990 and June 2010. 
Alpha-1, α1-antitrypsin deficiency emphysema; CF, cystic fibrosis; COPD, chronic obstructive pulmonary 
disease; IPF, idiopathic pulmonary fibrosis; PAH, pulmonary arterial hypertension—adapted from [38].
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Group 1 lung transplant recipients had higher incidence of primary graft dysfunction 
grade 3 and earlier time to chronic allograft dysfunction. There was no difference in 
the incidence of acute allograft rejection, cytopenias, or infections. Popescu et al. 
reported the increased risk of Cytomegalovirus (CMV) infections in the short telomere 
IPF lung transplant recipients [18]. Given this knowledge, some lung transplant cen-
ters will only accept CMV-negative donor lungs in order to reduce risk of transmission 
and CMV-related complications. In the case series of eight patients by Silhan et al., 
these lung transplant recipients with short telomere tolerated a dual drug immu-
nosuppression [20]. The antimetabolites could be easily withdrawn. Hematological 
complications occurred in four lung transplant recipients, with two cases of known 
bone marrow failure prior to lung transplantation. There was a 12% platelet transfu-
sion rate. Several patients had infectious complications with gram-negative pneu-
monia/sepsis, fungal infections, and CMV disease (pneumonitis). These patients 
developed acute kidney injury, with half of them requiring renal replacement therapy.
5. Studies on OFEV/Esbriet prior to lung transplantation
Many centers were initially reluctant to the use of nintedanib in IPF patient 
listed for lung transplant due to its potential to increase perioperative bleeding risk 
and impaired wound healing, thereby causing bronchial anastomotic complica-
tions. These concerns have been alleviated with recent publications that indicate 
no worsening of airway complications or bleeding risks [21, 22]. Four of the nine 
patients in Balestro et al.’s study required intraoperative venoarterial or veno-veno 
extracorporeal membrane oxygenation (ECMO) [21]. No patient experienced major 
bleeding, despite being on nintedanib as well as aspirin + clopidogrel. There were 
also no reports of airway anastomotic dehiscence.
The exact mechanism of action of pirfenidone may be from the inhibition of 
transforming growth factor beta (TGF-b) [23]. A few case reports describe the 
safety of pirfenidone use as a bridge to lung transplantation [24, 25].
Mortensen et al. reported the largest retrospective analysis of 18 IPF patients 
who took pirfenidone prior to lung transplantation [25]. Only one patient devel-
oped sternal dehiscence that was more related to a surgical issue. There was no 
airway dehiscence in any of the 18 patients.
6. Other preoperative immunosuppressive considerations
Many patients with sarcoidosis, hypersensitivity pneumonitis, and rheumato-
logically induced ILD require corticosteroids to help control respiratory symptoms 
and further lung parenchymal inflammation. Chronic steroid use can lead to 
thinning of the skin, myopathy, and delayed wound healing [26]. McAnally et al. 
reported the deleterious effects of pretransplant corticosteroids [27]. Sixty six 
percent of their patients awaiting lung transplantation were on corticosteroids. The 
132 patients in the low-dose steroid group (<0.42 mg/kg/m2) were compared to the 
69 high-dose steroid group (≥0.42 mg/kg/m2). Patients were clinically similar based 
on underlying lung disease, severity of lung function, transplant type, and donor 
lung ischemic time. The high-dose steroid group had higher rates of serious infec-
tions and delayed wound healing as well as higher risk of early posttransplant death. 
The general recommendations are not only to minimize the steroid dose to allow for 
continued stabilization of underlying ILD but also to minimize complications with 
bridge to lung transplantation.
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Lymphangioleiomyomatosis is characterized by proliferation of LAM cells, 
the abnormal smooth muscle-like cells that metastasize to lead cystic changes 
seen on chest radiograph. The cysts are present throughout both lung fields, 
although they predominate in the lower lung region. Their size can vary from 
3 mm up to 3 cm. Larger cysts (>0.5 cm) are more likely to cause pneumothoraces 
[28]. Pneumothoraces occur in up to 60–70% of women with LAM. A majority 
of first-time pneumothoraces occur in the third and fourth decade of life [29]. 
Unfortunately, they are not a one-time event for most LAM patients. Four percent 
of these individuals can have simultaneous bilateral pneumothoraces. Recurrence 
rates for pneumothoraces are upward of 70%. Sirolimus, an mTOR inhibitor, is 
currently recommended as therapy for LAM. It blocks the signaling pathway for 
the growth and proliferation of the LAM cells that cause all the clinical manifesta-
tions described. Common adverse events when taking sirolimus include mucositis, 
diarrhea, nausea, hypercholesterolemia, and lower extremity edema. The most 
relevant adverse events of sirolimus in the context of this chapter are poor wound 
healing and anastomotic dehiscence in perioperative periods [30–32]. Dilling et al. 
reported their experience of continued use of sirolimus in patients with LAM 
while awaiting lung transplantation [33]. All patients were continued on their 
maintenance sirolimus dose up to the day of lung transplantation. None of the 
patients developed increased bleeding or wound dehiscence. In select patients, the 
use of sirolimus may be required. Lymphangioleiomyomatosis can recur follow-
ing lung transplantation. It may present itself primarily as a chylous effusion. If a 
single-lung transplant is performed, the cystic lung disease can continue to prog-
ress. Sirolimus can be added to the maintenance immunosuppression to help the 
underlying process. There is varying reports on the safety of sirolimus use in early 
post-lung transplantation [31, 34].
7. Medical care of the lung transplant patient
The medical care after OLT requires close coordination between a multidisci-
plinary transplant team, including but not limited to transplant pulmonologists, 
cardiothoracic surgeons, pharmacists, physical/occupational/respiratory therapists, 
social workers, transplant nurses, and patient advocates. The transplant committee 
decision-making process for transplant eligibility is complex and beyond the scope 
of this text. However, important consideration elements of note are functional 
status, including physical ability to tolerate and recover from OLT [1]. To this end, 
physical therapy and nutritional optimization are paramount in the pretransplant 
process in order to ensure posttransplant success. Many inpatients that are listed for 
transplant have achieved benefit from early veno-venous extracorporeal membra-
nous oxygenation (VV-ECMO) in order to facilitate mobilization and engagement 
with physical therapy [35, 36].
Transplant infectious disease specialists can be helpful in directing region-
ally appropriate infectious disease screening/treatment prior to transplant. 
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) status assessments 
between donor and recipient are paramount in guiding postoperative antiviral 
therapy, with CMV +/− and CMV −/+ being prophylaxed with valganciclovir and 
CMV −/− receiving acyclovir. EBV status is helpful in determining immunosup-
pressive needs. Over-immunosuppression can increase the risk of posttransplant 
lymphoproliferative disorder (PTLD), a lymphoma-like condition that responds to 
reduction in immunosuppression. All lung transplant recipients receive high-dose 
glucocorticoid treatment and require pneumocystis prophylaxis, typically with 
trimethoprim-sulfamethoxazole.
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7.1 Complications following lung transplant
Acute rejection rates are extremely common in the first year after lung 
transplantation with approximately 30–40% of recipients having at least one 
episode in the first year after transplant. Triple-drug immunosuppressive agents 
have become the standard of care and are prescribed to minimize this risk [37]. 
Immunosuppressive dosing must be carefully considered so as to minimize acute 
rejection risk without leading way to infections. The regimen typically prescribed 
in lung and most solid organ transplants typically includes prednisone, a calcineu-
rin inhibitor (tacrolimus or cyclosporine), and an antimetabolite (azathioprine 
or mycophenolate mofetil). Despite the unique side effects of each of these drug 
classes, the cumulative effect of immunosuppression may predispose individuals to 
opportunistic infections, renal failure, malignancies, posttransplant hypertension, 
diabetes, and dyslipidemia. Table 1 reviews common drug interactions that can 
alter immunosuppressant clearance or therapeutic drug levels.
The lung allograft is subject to a variety of insults resulting in various paren-
chymal abnormalities. These complications are broadly classified as infectious and 
noninfectious. The development of infections is the leading cause of morbidity and 
mortality in the first 3 years following lung transplantation [38]. Bacterial patho-
gens are the most common, but fungal and viral infections are also particularly 
important (especially Aspergillus and Cytomegalovirus).
Despite their ubiquitous and potentially ominous nature, radiographic pulmo-
nary parenchymal abnormalities predicting posttransplant complication can be 
nonspecific (Figures 3–5). Bacterial and fungal radiographic features are highly 
varied and include consolidation, ill-defined nodules, cavitation, and ground-glass 
opacifications, making them difficult to identify. Viral infections (especially CMV) 
may have normal radiographs. They can also show ground-glass, micronodules, 
consolidation, and/or reticulonodular opacities.
Moreover, acute cellular rejection (ACR) can present similar to any of the previ-
ously mentioned complications. ACR radiographic features can appear as normal 
radiograph, ground-glass opacities, alveolar opacities, consolidation, nodules, as 
well as a new or evolving pleural effusion (seen in 43% of patients) [39, 40].
Due to the radiographic overlap in postoperative lung pathologies, broad-
spectrum antimicrobial therapy is often instituted in the acutely ill lung transplant 
Figure 3. 
Chest X-ray of a single-lung transplant recipient for IPF.
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recipient. A broad infectious differential must be maintained given the triple-drug 
immunosuppression when considering treatment options. Similarly, acute rejection 
is on the differential, and differentiating between the two is imperative. Clinical 
correlation and transbronchial biopsy are often indicated for discerning the diagno-
sis. The number of acute cellular rejections and infections contribute to a higher risk 
of developing chronic rejection.
Primary graft dysfunction (PGD) accounts for the main cause of death within 
the first 30 days following lung transplantation [38]. The underlying diagnosis lead-
ing to transplant is not predictive of developing PGD (restrictive disease with PGD 
22.1% vs. without PGD 20.3%) [37]. More recently, patients with IPF and associated 
pulmonary hypertension have been shown to have a higher incidence of developing 
PGD [41]. Moreover, higher pulmonary artery pressures impart a greater risk of 
developing severe PGD (grade 3).
Early diagnosis and management may impart a lower incidence of chronic 
allograft rejection. Chronic allograft rejection manifests as bronchiolitis 
Figure 5. 
Chest X-ray of a single right-lung transplant recipient for LAM.
Figure 4. 
Chest X-ray of a bilateral-lung transplant recipient for IPF.
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obliterans syndrome (BOS) or restrictive allograft syndrome (RAS). BOS is 
typically a progressive airflow limitation demonstrated on pulmonary function 
testing (PFT). Grading of BOS depends on the severity of airflow limitation 
relative to the patient’s best posttransplant FEV1. The radiographic presentations 
of BOS include a mixture of hypo- and hyperattenuation (mosaic attenuation) 
regions produced by air trapping and decreased peripheral vascularity, bronchi-
ectasis, and subsegmental atelectasis. RAS is hallmarked by upper lobe fibrosis. 
Radiographic RAS may have reticulonodular opacities, honeycombing, traction 
bronchiectasis, loss of lung volume, and interlobular septal thickening  
(Figure 6). In comparison to BOS however, these patients have restrictive  
physiology on PFTs [40, 42].
By bronchoscopy, the presence of eosinophilia and neutrophilia, airway infec-
tion and/or colonization, and acute cellular/lymphocytic bronchiolitis all impart 
increased risk of developing both BOS and RAS [37]. The underlying pathology 
necessitating transplant does not seem to influence the development of one form of 
chronic allograft rejection (24% BOS and 20.8% RAS).
Altering medications within therapeutic classes or augmenting existing therapy 
has been advocated when patients develop chronic rejection. There is clearly a 
small subset of patients who derive benefit from this therapy. However, alteration 
of immunosuppression may also increase the risk of opportunistic infections and 
development malignancy.
One alternative therapy for BOS is chronic azithromycin. Several small case 
series as well as one prospective, randomized, double-blind, placebo-controlled 
trial have suggested a benefit with azithromycin in lung transplant recipients 
[43–45]. Azithromycin may prevent the development of BOS, as well as treat a 
subset of patients with BOS. The mechanism for the positive effect of azithromycin 
in BOS prevention and treatment is believed to be related to its anti-inflammatory 
properties. Chronic azithromycin therapy is well tolerated. Gastrointestinal side 
effects, QTc prolongation, and auditory disturbances are common side effects. 
Clinicians should be aware that this medication is often taken chronically in lung 
transplant patients when considering antibiotic choices for acute respiratory infec-
tions in this population.
Figure 6. 
CT chest for a bilateral-lung transplant recipient for sarcoidosis in chronic allograft rejection.
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7.2 Airway complications
Currently, the bronchial anastomosis is created in an “end-to-end” fashion, 
and bronchial artery circulation is lost. Thus, the donor bronchus and anasto-
mosis depend solely on the poorly oxygenated pulmonary artery, portending 
to the development of local ischemia. Early complications (<3 months) from 
airway/anastomotic ischemia include necrosis and wound dehiscence. During 
the healing and remodeling phase (>3 months), typical complications are 
airway stenosis, granulation tissue accumulation, and malacia (typically a later 
occurrence). Graft rejection, immunosuppression, and bronchopulmonary 
infections have also been associated with airway complications. Lung transplant-
associated airway complications manifest in up to 30% of patients [46, 47]. 
Management strategies include airway dilation with silicone or self-expandable 
metallic stents, cryoablation, and laser photoresection. Airway stents are gener-
ally placed when respiratory symptoms are refractory to the abovementioned 
modalities (Figure 7). Most patients experience improvement in symptoms and 
lung function. However, complications from the above interventions include 
mucus plugging, obstructive granuloma, stent migration, fracture, or infectious 
colonization.
7.3 Complications of native lung in single-lung transplantation
It bears mention that patients’ native lung disease progression is not halted 
with the contralateral lung transplantation despite robust immunosuppression. 
The amount of native lung ground-glass opacification or fibrosis does not change 
or increases for the majority of single-lung transplant recipients with IPF [48]. 
Patients with IPF lose 10.8% of native lung volume and have an 11% increase in 
fibrosis in the first 4 years following SLT [49]. Up to 52% of the native lungs had 
evidence of fibrosis at the time of transplant, and this number grows to 92% at 
4 years posttransplant.
Common complications reported in IPF patients following SLT include bacterial 
or fungal infections, retention of secretions with associated airway obstruction 
and atelectasis, as well as pneumothoraces [50]. Moreover, posttransplant acute 
exacerbation of IPF is increasingly recognized [51]. Bronchogenic carcinomas 
have been reported at higher rates in single-lung transplant recipients. Significant 
Figure 7. 
Silicone endobronchial stent placed in a patient with anastomotic stricture development.
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contributing risk factors include advanced recipient or donor age, smoking history 
(>60 pack years), and COPD or IPF as the underlying lung disease [52].
7.4 Thromboembolic events following lung transplantation
Deep vein thrombus (DVT) and pulmonary emboli (PE) occur in up to 29% 
of lung transplant recipients. Two-thirds of these events occur in the first year 
of transplantation, and 20% of these events develop within the first month. 
Reduced mobility and recent surgery are risk factors. Inflammation also inhibits 
anticoagulant factors [53]. Other risk factors include, most notably, an underly-
ing diagnosis of IPF. Male gender, advanced age, pneumonia, diabetes mellitus, 
and utilization of cardiopulmonary bypass are other well-defined risk factors 
[41, 54]. Most of the pulmonary emboli occur within the allograft (86%)  
[54, 55].
The intrinsically thrombogenic surface of the allograft vasculature anas-
tomosis and increased allograft perfusion with concurrent drop in pulmonary 
vascular resistance in single-lung transplant recipients are postulated predilec-
tions for allograft predominant clot formation. Notably, clots can still occur in 
the native lung. Most posttransplant PEs are 5.8 months following lung trans-
plantation. Many centers advocate prophylactic anticoagulation for 6–9 months 
following transplant for this reason. Luckily, most patients tolerate an embolic 
event, even in the presence of large clot burden, without a loss of lung allograft 
function [56].
8. Conclusion
Lung transplantation is an important treatment option for patients with inter-
stitial lung disease after medical therapy has failed. However, pulmonary fibrosis 
patients have the worst survival following lung transplantation. Nonetheless, there 
is a survival advantage for those with pulmonary fibrosis who proceed with lung 
transplant [57, 58]. Moreover, lung transplantation improves quality of life. ISHLT 
registry data denotes that lung transplant recipients have better quality of life, 
general health, and many are even able return to work. Up to 30% of patients are 
working at 1 year, and 50% are working at 5 years [59–62].
Lung transplantation, however, is not without its risks, and patient awareness 
of these risks is important before lung transplantation is entertained or pursued. 
All appropriate measures should be taken to mitigate risk factors surrounding lung 
transplantation. So doing can potentially improve long-term outcomes. Lastly, as a 
growing number of lung transplant recipients make their way into the community, 
the onus for and access to working lung transplant knowledge now extend far 
beyond the transplant center, into our communities at large.
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